Related Experiment Video
Updated: Jun 13, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Moxifloxacin: update and perspectives after 8 years of usage
Hartmut M Lode1, Malina Schmidt-Ioanas
1RCMS Institute for Clinical Pharmacology, Charitè - Universitätsmedizin Berlin, Hohenzollerndamm 2, D10717 Berlin, Germany. haloheck@zedat.fu-berlin.de
Abstract:
Moxifloxacin has a broad spectrum of activity, including Gram-positive and Gram-negative organisms, atypical respiratory pathogens, anaerobes and penicillin- and macrolide-resistant Streptococcus pneumoniae. It achieves good tissue penetration and high concentrations in clinically relevant tissues and fluids. It is available in both an oral and intravenous formulation, has a once-daily administration and a good tolerance and safety profile. Moxifloxacin is used mainly for the treatment of acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute bacterial sinusitis, complicated skin and skin-structure infections and complicated intra-abdominal infections, as well as pulmonary TB, although it is not approved in this indication. The most recent studies covering these clinical indications are discussed.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
FDA Approved Drugs: Changes to Approved Drugs
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
